156 related articles for article (PubMed ID: 24669768)
1. Therapeutic potential of apigenin, a plant flavonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells.
Solmaz S; Adan Gokbulut A; Cincin B; Ozdogu H; Boga C; Cakmakoglu B; Kozanoglu I; Baran Y
Nutr Cancer; 2014; 66(4):599-612. PubMed ID: 24669768
[TBL] [Abstract][Full Text] [Related]
2. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells.
Gucluler G; Baran Y
Hematology; 2009 Jun; 14(3):139-44. PubMed ID: 19490758
[TBL] [Abstract][Full Text] [Related]
4. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
[TBL] [Abstract][Full Text] [Related]
5. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
6. RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells.
Wang H; Yu J; Zhang L; Xiong Y; Chen S; Xing H; Tian Z; Tang K; Wei H; Rao Q; Wang M; Wang J
Biochem Biophys Res Commun; 2014 Apr; 446(4):1204-10. PubMed ID: 24680683
[TBL] [Abstract][Full Text] [Related]
7. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.
Baran Y; Bielawski J; Gunduz U; Ogretmen B
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1535-44. PubMed ID: 21833718
[TBL] [Abstract][Full Text] [Related]
8. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
9. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
11. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM
Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678
[TBL] [Abstract][Full Text] [Related]
12. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
13. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
15. (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
Meng Y; Li Y; Li J; Li H; Fu J; Liu Y; Liu H; Chen X
Leuk Lymphoma; 2007 Nov; 48(11):2204-12. PubMed ID: 17926190
[TBL] [Abstract][Full Text] [Related]
16. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.
Dong Y; Xiong M; Duan L; Liu Z; Niu T; Luo Y; Wu X; Xu C; Lu C
Apoptosis; 2014 Aug; 19(8):1281-92. PubMed ID: 24830786
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.
Kurosu T; Wu N; Oshikawa G; Kagechika H; Miura O
Apoptosis; 2010 May; 15(5):608-20. PubMed ID: 20094798
[TBL] [Abstract][Full Text] [Related]
18. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts.
Ekiz HA; Can G; Gunduz U; Baran Y
Hematology; 2010 Feb; 15(1):33-8. PubMed ID: 20132660
[TBL] [Abstract][Full Text] [Related]
20. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
